| Title |
Format |
Date Published |
Recommendations for Use of an Isoniazid–Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection
MMWR 2011; 60:1650–1653
|
PDF
(1.1 MB) |
12/2011 |
Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010
MMWR 2010; 59 (RR-5); 1-25
|
PDF
(502 KB) |
6/2010 |
Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children
MMWR 2009; 58: 1-166 |
PDF
(2.2MB) |
3/2009 |
Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
MMWR 2009; 58: 1-198 |
PDF
(2.2MB) |
3/2009 |
Plan to Combat Extensively
Drug-Resistant Tuberculosis
MMWR 2009; 58 (RR-03) |
PDF
(752KB) |
2/2009 |
Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis
MMWR 2009; 58 (01); 7-10 |
PDF |
1/2009 |
| Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States |
|
11/2008 |
|
Report of an Expert
Consultation on the Uses of Nucleic Acid Amplification Tests for
the Diagnosis of Tuberculosis |
|
11/2008 |
|
Notice to Readers:
Updated Guidelines on Managing Drug Interactions
in the Treatment
of HIV-Related Tuberculosis |
PDF |
1/2008 |
|
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis |
PDF |
1/2008 |
Prevention and Control of Tuberculosis in Correctional and
Detention Facilities: Recommendations from CDC
MMWR 2006; 55 (No. RR–09, 1–44) |
PDF |
7/2006 |
Guidelines for Preventing the Transmission of Mycobacterium
tuberculosis in Health-Care Settings, 2005
MMWR 2005; 54 (No. RR-17) – Reprint
Note: The errata was removed. The corrections included in the errata have been incorporated into the reprinted guidelines.
|
PDF |
12/2005 |
|
Health
Information for International Travel |
|
1/2005–2006 |
Guidelines for Using the QuantiFERON–TB Gold Test for Detecting
Mycobacterium tuberculosis Infection, United States
MMWR 2005; 54 (No. RR–15, 1–37) |
PDF |
12/2005 |
Guidelines for the Investigation of Contacts of Persons
with Infectious Tuberculosis: Recommendations from the
National Tuberculosis Controllers Association and CDC
MMWR 2005; 54 (No. RR–15, 1–37) |
PDF |
12/2005 |
Controlling Tuberculosis in the United States
Recommendations
from the American Thoracic Society, CDC, and the Infectious
Diseases Society of America
MMWR 2005; 54 (No. RR–12) |
PDF |
11/2005 |
National Plan for Reliable Tuberculosis Laboratory Services
Using a Systems Approach
MMWR 2005; 54 (RR–6) |
PDF |
4/2005 |
Errata: Treatment of Tuberculosis
MMWR 2005; 52 (RR–11) |
PDF |
1/2005 |
New CDC Program for Rapid Genotyping of Mycobacterium tuberculosis Isolates
MMWR 2005; 54 (No. 02) |
PDF |
1/2005 |
Treating Opportunistic Infections Among HIV–Infected Adults
and Adolescents
MMWR 2004; 53 (RR15) |
PDF |
12/2004 |
Treating Opportunistic Infections Among HIV–Exposed and
Infected Children
MMWR 2004; 53 (RR14) |
PDF |
12/2004 |
Tuberculosis Associated with Blocking Agents Against Tumor
Necrosis Factor – Alpha – California, 2002–2003
MMWR 2004; 53 (No. 30) |
PDF |
8/2004 |
|
Guide to the Application
of Genotyping to Tuberculosis Prevention and Control |
PDF |
6/2004 |
Update: Adverse Event Data and Revised American Thoracic
Society/CDC Recommendations Against the Use of Rifampin
and Pyrazinamide for Treatment of Latent Tuberculosis Infection
MMWR 2003; 52 (No. 31) |
PDF |
8/2003 |
Treatment of Tuberculosis
MMWR 2003; 52 (No. RR–11)
|
PDF |
6/2003 |
Guidelines for Environmental Infection Control in Health–Care
Facilities
MMWR 2003; 52 (No. RR–10) |
PDF |
6/2003 |
Timing of Tuberculosis Screening and Smallpox Vaccination
– Recommendations for Using Smallpox Vaccine in a Pre–Event
Vaccination Program
MMWR 2003; 52 (No. RR–7) |
PDF |
4/2003 |
Guidelines for Preventing Opportunistic Infections Among
HIV–Infected Persons — 2002
MMWR 2002; 51 (No. RR–8) |
PDF |
6/2002 |
Progressing Toward Tuberculosis Elimination in Low–Incidence
Areas of the United States
MMWR 2002; 51 (No. RR–5) |
PDF |
5/2002 |
General Recommendations on Immunization: Recommendations
of the Advisory Committee on Immunization Practices (ACIP)
and the American Academy of Family Physicians (AAFP)
MMWR 2002; 51 (No. RR–2). |
PDF |
2/2002 |
Preventing and Controlling Tuberculosis Along the U.S.–Mexico
Border Work Group Report
MMWR 2001; 50 (No. RR–1) |
PDF |
1/2001 |
Update: Nucleic Acid Amplification Tests for Tuberculosis
MMWR 2000; 49 (No. 26) |
PDF |
7/2000 |
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis
Infection
MMWR 2000; 49 (No. RR–6)
Updates |
PDF |
6/2000 |
Updated Guidelines for the Use of Rifabutin or Rifampin
for the Treatment and Prevention of Tuberculosis Among HIV–Infected
Patients Taking Protease Inhibitors or Nonnucleoside Reverse
Transcriptase Inhibitors
MMWR 2000; 49 (No. 9) |
PDF |
3/2000 |
| Diagnostic Standards / Classification of
TB in Adults and Children — Am J Respir Crit Care Med 2000;
161 |
PDF |
2000 |
Tuberculosis Elimination Revisited: Obstacles, Opportunities,
and a Renewed Commitment (ACET)
MMWR 1999; 48 (No. RR–9) |
PDF |
8/1999 |
Recommendations for Prevention and Control of Tuberculosis
among Foreign–Born Persons
MMWR 1998; 47 (No. RR–16) |
PDF |
9/1998 |
Development of new Vaccines for Tuberculosis
MMWR 1998; 47 (No. RR–13) |
PDF |
8/1998 |
Nucleic Acid Amplification Tests for Tuberculosis.
MMWR 1996; 45 (No. 43)
|
PDF |
11/1996 |
Prevention and Control of Tuberculosis in Correctional Facilities
(ACET)
MMWR 1996; 45 (No. RR–8) |
PDF |
6/1996 |
The Role of BCG Vaccine in the Prevention and Control of
Tuberculosis in the United States. (ACET and ACIP)
MMWR 1996; 45 (RR–4) |
PDF |
4/1996 |
Essential Components of a Tuberculosis Prevention and Control
Program (ACET)
MMWR 1995; 44 (No. RR–11) |
PDF |
9/1995 |
Tuberculosis Control Laws – United States, 1993 (ACET)
MMWR 1993; 42 (No. RR–15) |
PDF |
11/1993 |
Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of Vaccines and Immune Globulins in
Persons with Altered Immunocompetence
MMWR 1993; 42 (No. RR-4)
|
PDF |
04/1993 |
